5.78

3.03% 0.17

Iovance Biotherapeutics Inc (IOVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IOVA? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$5.61

Offen:

$5.69

24-Stunden-Volumen:

10.86M

Relative Volume:

1.47

Marktkapitalisierung:

$1.76B

Einnahmen:

$32.77M

Nettoeinkommen (Verlust:

$-440.22M

KGV:

-3.4611

EPS:

-1.67

Netto-Cashflow:

$-400.48M

1W Leistung:

+3.77%

1M Leistung:

-1.70%

6M Leistung:

-51.14%

1J Leistung:

-63.35%

1-Tages-Spanne:

$5.675

$6.09

1-Wochen-Bereich:

$5.44

$6.09

52-Wochen-Spanne:

$5.05

$18.33

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Firmenname

Iovance Biotherapeutics Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (678)

Telefon

(650) 260-7120

Adresse

825 INDUSTRIAL ROAD, SAN CARLOS

Mitarbeiter

557

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

IOVA's Discussions on Twitter

Vergleichen Sie IOVA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IOVA Iovance Biotherapeutics Inc	5.78	1.76B	32.77M	-440.22M	-400.48M	-1.67
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-24	Eingeleitet	UBS	Buy
2024-07-29	Herabstufung	Piper Sandler	Overweight → Neutral
2023-11-20	Eingeleitet	Goldman	Buy
2023-09-18	Bestätigt	Barclays	Overweight
2023-05-30	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-27	Fortgesetzt	Wells Fargo	Equal Weight
2023-01-27	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-09	Herabstufung	Goldman	Buy → Neutral
2022-10-31	Eingeleitet	Guggenheim	Neutral
2022-08-18	Fortgesetzt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Stifel	Hold → Buy
2021-12-07	Fortgesetzt	Cowen	Outperform
2021-06-10	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Herabstufung	Piper Sandler	Overweight → Neutral
2021-05-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Herabstufung	Stifel	Buy → Hold
2021-05-03	Eingeleitet	Truist	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2021-03-08	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-10-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-22	Eingeleitet	Mizuho	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-02-26	Bestätigt	Oppenheimer	Outperform
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-10-01	Eingeleitet	Stifel	Buy
2019-04-29	Eingeleitet	Piper Jaffray	Overweight
2019-02-28	Bestätigt	Chardan Capital Markets	Buy
2019-02-07	Eingeleitet	Robert W. Baird	Outperform
2018-12-31	Fortgesetzt	B. Riley FBR	Buy
2018-07-06	Bestätigt	Chardan Capital Markets	Buy
2018-04-10	Hochstufung	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Bestätigt	B. Riley FBR, Inc.	Neutral
2018-02-23	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Bestätigt	H.C. Wainwright	Buy
2017-11-01	Bestätigt	B. Riley FBR, Inc.	Buy

Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

Feb 21, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Feb 21, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 21, 2025

Iovance Biotherapeutics (IOVA) to Release Quarterly Earnings on Wednesday - MarketBeat

Feb 21, 2025

Feb 20, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Rice Hall James & Associates LLC - MarketBeat

Feb 20, 2025

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know - Nasdaq

Feb 20, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Iovance Biotherapeutics, Inc. (IOVA) - ACCESS Newswire

Feb 20, 2025

Biotech Spotlight: Iovance's Crucial Year-End Results & TIL Therapy Updates Coming Feb 27 - StockTitan

Feb 18, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.3%Time to Buy? - MarketBeat

Feb 18, 2025

Feb 17, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Banque Pictet & Cie SA - MarketBeat

Feb 17, 2025

Feb 14, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 1-Year LowShould You Sell? - MarketBeat

Feb 14, 2025

Feb 12, 2025

Executive Compensation Alert: Iovance's Strategic Move with 305K Share Package for Commercial Chief - StockTitan

Feb 12, 2025

Stifel maintains Buy on Iovance Biotherapeutics, target at $21 - MSN

Feb 12, 2025

Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - AOL

Feb 12, 2025

(IOVA) Trading Report - Stock Traders Daily

Feb 12, 2025

Iovance Biotherapeutics appoints new chief commercial officer - MSN

Feb 12, 2025

Feb 11, 2025

Jennison Associates LLC Buys Shares of 66,568 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Feb 11, 2025

Feb 10, 2025

Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma - Marketscreener.com

Feb 10, 2025

Iovance Biotherapeutics Shares Fell Today: What's Going On? - Benzinga

Feb 10, 2025

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 - br.ADVFN.com

Feb 10, 2025

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer - GlobeNewswire

Feb 10, 2025

Iovance Lands Former Celgene & BMS Executive to Accelerate TIL Therapy Commercialization | $IOVA - StockTitan

Feb 10, 2025

Feb 08, 2025

What's Going On With Iovance Biotherapeutics Today? - MSN

Feb 08, 2025

Feb 07, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low on Analyst Downgrade - MarketBeat

Feb 07, 2025

Feb 06, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low on Analyst Downgrade - MarketBeat

Feb 06, 2025

SG Americas Securities LLC Purchases Shares of 69,625 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Feb 06, 2025

Feb 04, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $7.50 at Piper Sandler - MarketBeat

Feb 04, 2025

Feb 03, 2025

Oversold Conditions For Iovance Biotherapeutics (IOVA) - Nasdaq

Feb 03, 2025

Feb 02, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 Consensus Target Price from Analysts - MarketBeat

Feb 02, 2025

Feb 01, 2025

What's Wrong With Iovance Biotherapeutics Stock? - MSN

Feb 01, 2025

Institutional owners may consider drastic measures as Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) recent US$122m drop adds to long-term losses - Simply Wall St

Feb 01, 2025

(IOVA) Investment Report - Stock Traders Daily

Feb 01, 2025

Lion Biotechnologies, Inc. Appoints Michael T. Lotze, MD, as Chief Scientific Officer and Vice President of Research and Development - Marketscreener.com

Feb 01, 2025

Jan 31, 2025

Stifel maintains Buy on Iovance stock with $21 target - MSN

Jan 31, 2025

Jan 29, 2025

Where Will Iovance Biotherapeutics Be in 5 Years? - MSN

Jan 29, 2025

Jan 28, 2025